Pancreatic resection with perioperative drug repurposing of propranolol and etodolac: trial protocol of the phase-II randomised placebo controlled PROSPER trial
Introduction Pancreatic cancer is the fourth-leading cause of cancer-related death in developed countries. Despite advances in systemic chemotherapy, the mainstay of curative therapy for non-metastatic disease is surgical resection. However, the perioperative period is characterised by stress and in...
Saved in:
Main Authors: | Phillip Knebel, Thilo Hackert, Markus W Büchler, Ilse Rooman, Markus K Diener, Felix J Hüttner, André L Mihaljevic, Oliver Strobel, Gauthier Bouche, Johannes Hüsing |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2020-09-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/10/9/e040406.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Protocol of a randomised controlled phase II clinical trial investigating PREoperative endoscopic injection of BOTulinum toxin into the sphincter of Oddi to reduce postoperative pancreatic fistula after distal pancreatectomy: the PREBOTPilot trial
by: Phillip Knebel, et al.
Published: (2020-09-01) -
Unlocking new potential: the evolving landscape of metformin repurposing trials
by: Yating Zhou, et al.
Published: (2025-01-01) -
IUPHAR review: Drug repurposing in Schizophrenia – An updated review of clinical trials
by: Jihan K. Zaki, et al.
Published: (2025-03-01) -
Etodolac Single Dose Metabolic Profile Elucidation: Pharmacokinetics and Adverse Events in Healthy Volunteers
by: Karen Sánchez-Luquez, et al.
Published: (2025-01-01) -
A Validated HPLC-DAD Method for Simultaneous Determination of Etodolac and Pantoprazole in Rat Plasma
by: Ali S. Abdelhameed, et al.
Published: (2014-01-01)